Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is making significant strides in the development of its peptide-based therapeutics, particularly with rusfertide and icotrokinra. They have addressed potential safety issues with rusfertide and have a strong pipeline with several potential catalysts on the horizon, including potential partnerships for their obesity drugs. With a strong cash position and potential peak market opportunities exceeding $10 billion, PTGX is well-positioned for long-term success.

Bears say

Protagonist Therapeutics is experiencing a positive launch for Icotyde, with strong prescriber growth and commercial coverage. However, their other pipeline candidates, such as PN-881 for obesity, are still in the early stages of development and their success is uncertain. Additionally, the Ph2 trial design for their IL-17 program will be a key factor in determining the potential of PN-881, and investors should closely monitor its progress. Protagonist Therapeutics has a promising pipeline but also faces significant risks and uncertainties, leading to a negative outlook.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Strong Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.